"Bioponic"), an innovative provider of natural products and patented technology serving the Complementary Alternative Medicine (CAM) and nutraceutical markets, announced today the launch of Curemisinin(TM), an all-natural anti-malaria product that is based on three proven effective anti-malaria herbs: Artemesia, Turmeric and Cinchona Bark, uniquely extracted through the Company's proprietary extraction/distillation technologies. This binary product comprises a nasal spray (Curemisinin A) with an oral spray (Curemisinin B) to treat malaria in the quickest, most effective manner.
Malaria is a disease caused by a blood parasite transmitted by mosquitoes, and the number one killer in sub-Saharan Africa, killing more than a million people worldwide, every year. The majority of those who die from malaria are African children, according to the Centers for Disease Control. Through Bioponic's international alliance with Hyperdynamics Corp, Curemisinin is currently being disseminated free-of-charge in clinics located in the capital city of Guinea, Africa. The efficacy of Bioponic's Curemisinin will be recorded, and provide valuable data over the next several weeks on the product's ability to treat malaria in humans.
Bioponic's Chairman and CEO Steven M. Schorr remarked, "Curemisinin's use of a nasal delivery system allows the bioresonant liquid remedy to be delivered directly to the brain via the nasal membrane. This may have a significant impact on Cerebral Malaria, a condition primarily affecting children, who die within 24 to 72 hours without treatment. Bioponic not only hopes to stop the track of cerebral malaria, but potentially help bring down the cost of treatment and increase the efficacy of treatments for all types of malaria, especially resistant strains of the disease."
As evolving pathogens develop widespread resistance to over-prescribed antibiotics, antivirals and antimalarial drugs, the use of natural medicines is being recommended for their proven efficacy, even by the World Health Organization, who has indicated the benefits of artemisinin-based combination therapies (ACTs) as the front line of treatment for the vast malaria problem. For more information on Bioponic and Curemisinin, visit http://www.bioponic.com.
About Bioponic Phytoceuticals
Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products. The Company has developed several branded product lines, including the nasal spray: Flight Spray® (http://www.flightspray.com); Curecumin(TM) (a treatment for Alzheimer's Disease); O-Spray(TM) (scented nasal sprays); Throat Note(TM) (formulated for professional speakers and singers, great for everyone!) and the effective natural skincare product Hawaiian Healing Mist(TM). Bioponic is focused on the production of natural products that are used to promote health and well-being.
All statements other than statements of historical fact included in this press release are "forward-looking statements" within the meaning of federal securities laws. Such forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the Company's control.
CONTACT: Steven M. Schorr, CEO, Bioponic Phytoceuticals, +1-808-876-1711, firstname.lastname@example.org or Geoffrey Eiten, Investor Relations, OTC Financial Network, 781-444-6100x613, email@example.com, http://www.otcfn.com/bpyt.